Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2026
Reporting Period: Single event date (June 2, 2026)
Business Context: The registrant is an emerging growth company incorporated in Delaware, trading on the Nasdaq Capital Market. The filing announces a corporate event regarding its CyPath® Lung product.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K reports a specific corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the announcement of an upcoming webinar.
Guidance, Outlook, and Management Commentary
- Event Announcement: On June 2, 2026, the company announced that the Society for Advanced Bronchoscopy (SAB) will host a webinar.
- Topic: The webinar will cover the expanding role of CyPath® Lung in pulmonary, oncology, and surgical practices for the detection and management of early-stage lung cancer.
- Exhibits: A press release detailing this event is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the date and agenda of the Society for Advanced Bronchoscopy (SAB) webinar regarding CyPath® Lung.
- Review the full text of the press release attached as Exhibit 99.1 for specific clinical data or market commentary.
- Confirm the company's status as an emerging growth company and its compliance with related reporting standards.